Palvella Therapeutics PVLA
NASDAQ PVLA
$157.24 +1.77 (+1.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Palvella Therapeutics (PVLA) Total Debt (2013 - 2025)

Palvella Therapeutics (PVLA) posted quarterly Total Debt of $1.3 million for Q4 2014, down 23.08% year-over-year from $1.7 million in Q4 2013, and up 32083.51% quarter-over-quarter from $3948.0 in Q3 2014.

Analysis

Palvella Therapeutics (PVLA) Total Debt (2013 - 2025) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Total Debt for 2 consecutive years, with $1.3 million the latest figure, recorded in Q4 2014.

  • In Q4 2014, Total Debt fell 23.08% year-over-year to $1.3 million; the TTM figure through Dec 2014 stood at $1.3 million (down 23.08% YoY), while the FY2014 annual figure was $1.3 million, down 23.08% from the prior year.
  • Total Debt advanced to $1.3 million in Q4 2014 per PVLA's latest filing, from $3948.0 in the prior quarter.
  • Across five years, Total Debt topped out at $1.7 million in Q4 2013 and bottomed at $474.0 in Q2 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.34 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Palvella Therapeutics 2.24 Bn 1.93 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.20 Mn
Sep 30, 2025 2.22 Mn
Jun 30, 2025 1.98 Mn
Mar 31, 2025 1.98 Mn
Dec 31, 2024 1.98 Mn
Dec 31, 2014 1.27 Mn
Sep 30, 2014 3,948.00
Jun 30, 2014 948.00
Mar 31, 2014 2,474.00
Dec 31, 2013 1.65 Mn
Jun 30, 2013 474.00